Latest filings (excl ownership)
DEF 14A
Definitive proxy
29 Apr 24
8-K
Changes in Registrant's Certifying Accountant
5 Apr 24
8-K
Regulation FD Disclosure
19 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K/A
Results of Operations and Financial Condition
14 Mar 24
8-K
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
7 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
26 Sep 23
8-K
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
14 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
7 Aug 23
424B5
Prospectus supplement for primary offering
7 Aug 23
8-K
Regulation FD Disclosure
14 Jul 23
8-K
Regulation FD Disclosure
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
9 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Regulation FD Disclosure
28 Apr 23
8-K
Entry into a Material Definitive Agreement
21 Apr 23
8-K
Regulation FD Disclosure
11 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
8-K
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
28 Mar 23
8-K
Termination of a Material Definitive Agreement
17 Mar 23
EFFECT
Notice of effectiveness
3 Jan 23
CORRESP
Correspondence with SEC
30 Dec 22
UPLOAD
Letter from SEC
29 Dec 22
S-3
Shelf registration
23 Dec 22
8-K
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
13 Dec 22
8-K
Regulation FD Disclosure
13 Dec 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
9 Nov 22
8-K
Entry into a Material Definitive Agreement
4 Nov 22
8-K
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
1 Nov 22
8-K
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of
1 Sep 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
9 Aug 22
S-8
Registration of securities for employees
30 Jun 22
Latest ownership filings
SC 13G/A
BlackRock Inc.
5 Apr 24
4
Pad Chivukula
27 Mar 24
4
Pad Chivukula
21 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Nikko Asset Management Americas, Inc.
12 Feb 24
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
SC 13G/A
FEDERATED HERMES, INC.
17 Jan 24
4
ANDY SASSINE
19 Dec 23
4
Pad Chivukula
19 Dec 23
4
Lance Kurata
19 Dec 23
4
Keith C Kummerfeld
19 Dec 23
4
Joseph E Payne
19 Dec 23
4
Pad Chivukula
3 Nov 23
SC 13G/A
STATE STREET CORP
10 Oct 23
4
Pad Chivukula
4 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
4
Pad Chivukula
5 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
ANDY SASSINE
17 Aug 23
4
Pad Chivukula
3 Aug 23
4
John Markels
3 Aug 23
4
PETER C FARRELL
3 Aug 23
4
Jing L. Marantz
3 Aug 23
4
EDWARD W HOLMES
3 Aug 23
4
JAMES F BARLOW
3 Aug 23
4
Magda Marquet
3 Aug 23
144
Notice of proposed sale of securities
1 Aug 23
4
Pad Chivukula
18 Jul 23
4
Keith C Kummerfeld
18 Jul 23
144
Notice of proposed sale of securities
14 Jul 23
144
Notice of proposed sale of securities
14 Jul 23
4
Pad Chivukula
7 Jul 23
4
Pad Chivukula
5 Jun 23
4
Pad Chivukula
12 May 23
144
Notice of proposed sale of securities
11 May 23
144
Notice of proposed sale of securities
10 May 23